Bank­rupt uBio­me sells off patents, da­ta for $7M; J&J buys op­tions on Pul­ma­trix's lung can­cer drugs

→ In the fi­nal chap­ter of dis­graced gut test­ing play­er uBio­me’s sto­ry, Pso­ma­gen has ac­quired all its key as­sets in a fire sale, in­clud­ing 246 mi­cro­bio­me patents, anonymized da­ta, near­ly 300,000 sam­ples and equip­ment from uBio­me’s lab in San Fran­cis­co. Pso­ma­gen is the Rockville, MD-based unit of Ko­re­an se­quenc­ing com­pa­ny Macro­gen. For an idea of just how low the once high-fly­ing start­up has sunk since the FBI launched an in­ves­ti­ga­tion over its busi­ness prac­tices, here’s the kick: “The ac­qui­si­tion price is USD 7.05 mil­lion, cor­re­spond­ing to 1% of uBio­me’s es­ti­mat­ed cor­po­rate val­ue.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.